{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:43:09Z","timestamp":1768963389513,"version":"3.49.0"},"reference-count":40,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1027"],"award-info":[{"award-number":["20FC1027"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23AA2003"],"award-info":[{"award-number":["23AA2003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1031"],"award-info":[{"award-number":["23FC1031"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite warnings from the US Food and Drug Administration about respiratory adverse events associated with gabapentinoids, direct evidence of their risk in patients with asthma is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a national administrative claims database, we prepared two active comparators\u2014new user cohorts of patients with a history of neuropathic or chronic pain and asthma\u2014initiating gabapentinoids and comparator drugs (tricyclic antidepressants (TCAs) or serotonin norepinephrine reuptake inhibitors (SNRIs)). Overlap propensity score weighting was used to control for potential confounders. The initial occurrence of asthma exacerbation requiring systemic corticosteroids (primary) or those requiring hospitalisation for asthma (secondary) was assessed using a weighted Cox proportional hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>In the TCAs cohort (171\u2009393 gabapentinoids users and 5916 TCAs users), gabapentinoids use was associated with a higher incidence of primary (59.4 vs 33.7 per 100 person-years; HR 1.46, 95% CI 1.34 to 1.60) and secondary outcomes (0.91 vs 0.42 per 100 person-years; 2.02, 1.11 to 3.68). In the SNRIs cohort (189\u2009055 gabapentinoids users and 19\u2009800 SNRIs users), using gabapentinoids was also associated with a higher incidence of primary outcome (63.5 vs 42.8 per 100 person-years; HR 1.24, 1.19 to 1.30). However, the difference in the secondary outcome did not reach statistical significance (0.93 vs 0.68 per 100 person-years; 1.24, 0.94 to 1.63).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Gabapentinoids were associated with an increased risk of asthma exacerbations compared with TCAs or SNRIs. Managing neuropathic or chronic pain in patients with asthma using gabapentinoids should be approached with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223240","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T01:30:38Z","timestamp":1756085438000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Gabapentinoids and risk for asthma exacerbations: a nationwide retrospective cohort study"],"prefix":"10.1136","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1649-0596","authenticated-orcid":false,"given":"Yuya","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"},{"name":"Clinical Research Center, NHO Tokyo National Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisuke","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan"},{"name":"Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan"},{"name":"Department of Clinical Data Management and Research, Clinical Research Center, National Hospital Organization Headquarters, Tokyo, Japan"},{"name":"Institute of Clinical Epidemiology (iCE), Showa Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Suzukawa","sequence":"additional","affiliation":[{"name":"Clinical Research Center, NHO Tokyo National Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sasabuchi","sequence":"additional","affiliation":[{"name":"Department of Real-world Evidence, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,24]]},"reference":[{"key":"2026012006550576000_81.2.121.1","doi-asserted-by":"crossref","unstructured":"Gibson PG , Vertigan AE . Management of chronic refractory cough. BMJ 2015;351. doi:10.1136\/bmj.h5590","DOI":"10.1136\/bmj.h5590"},{"key":"2026012006550576000_81.2.121.2","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2213-2600(23)00042-5","article-title":"Sedative medications: an avoidable cause of asthma and COPD exacerbations?","volume":"11","author":"Chalitsios","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012006550576000_81.2.121.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12358"},{"key":"2026012006550576000_81.2.121.4","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jama.2022.13659","article-title":"Growing role of gabapentin in opioid-related overdoses highlights misuse potential and off-label prescribing practices","volume":"328","author":"Kuehn","year":"2022","journal-title":"JAMA"},{"key":"2026012006550576000_81.2.121.5","doi-asserted-by":"crossref","unstructured":"Torjesen I . Pregabalin and gabapentin: what impact will reclassification have on doctors and patients? BMJ 2019;364. doi:10.1136\/bmj.l1107","DOI":"10.1136\/bmj.l1107"},{"key":"2026012006550576000_81.2.121.6","unstructured":"UK Government . Pregabalin and gabapentin to be controlled as class C drugs. Available: https:\/\/www.gov.uk\/government\/news\/pregabalin-and-gabapentin-to-be-controlled-as-class-c-drugs [Accessed 1 Apr 2024]."},{"key":"2026012006550576000_81.2.121.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60776-4"},{"key":"2026012006550576000_81.2.121.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-1271"},{"key":"2026012006550576000_81.2.121.9","doi-asserted-by":"crossref","unstructured":"Morice AH , Millqvist E , Bieksiene K , et al . ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 2020;55. doi:10.1183\/13993003.01136-2019","DOI":"10.1183\/13993003.01136-2019"},{"key":"2026012006550576000_81.2.121.10","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-1496"},{"key":"2026012006550576000_81.2.121.11","unstructured":"U.S. FOOD & DRUG ADMINISTRATION . FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin [Accessed 1 Apr 2024]."},{"key":"2026012006550576000_81.2.121.12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.7326\/M23-0849","article-title":"Gabapentinoids and risk for severe exacerbation in chronic obstructive pulmonary disease\u202f: a population-based cohort study","volume":"177","author":"Rahman","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026012006550576000_81.2.121.13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.37737\/ace.1.2_28","article-title":"Real World Data in Japan: chapter I NDB","volume":"1","author":"Yasunaga","year":"2019","journal-title":"ACE"},{"key":"2026012006550576000_81.2.121.14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00540-018-2501-0","article-title":"Executive summary of the Clinical Guidelines of Pharmacotherapy for Neuropathic Pain: second edition by the Japanese Society of Pain Clinicians","volume":"32","author":"Sumitani","year":"2018","journal-title":"J Anesth"},{"key":"2026012006550576000_81.2.121.15","unstructured":"Clinical practice guidelines for the management of chronic pain. Available: https:\/\/minds.jcqhc.or.jp\/common\/wp-content\/plugins\/pdfjs-viewer-shortcode\/pdfjs\/web\/viewer.php?file=https:\/\/minds.jcqhc.or.jp\/common\/summary\/pdf\/c00664.pdf&dButton=false&pButton=false&oButton=false&sButton=true#zoom=auto&pagemode=none&_wpnonce=3b871a512b [Accessed 1 Apr 2024]."},{"key":"2026012006550576000_81.2.121.16","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN) . Management of chronic pain: a national clinical guideline [online]. Available: https:\/\/www.sign.ac.uk\/media\/2097\/sign136_2019.pdf [Accessed 1 Apr 2024]."},{"key":"2026012006550576000_81.2.121.17","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1794"},{"key":"2026012006550576000_81.2.121.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.12.983"},{"key":"2026012006550576000_81.2.121.19","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.2016.1260466"},{"key":"2026012006550576000_81.2.121.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00645.x"},{"key":"2026012006550576000_81.2.121.21","doi-asserted-by":"crossref","unstructured":"Marshall A , Altman DG , Holder RL , et al . Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 2009;9. doi:10.1186\/1471-2288-9-57","DOI":"10.1186\/1471-2288-9-57"},{"key":"2026012006550576000_81.2.121.22","doi-asserted-by":"crossref","unstructured":"Pradhan R , Lu S , Yin H , et al . Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ 2022;379. doi:10.1136\/bmj-2022-071380","DOI":"10.1136\/bmj-2022-071380"},{"key":"2026012006550576000_81.2.121.23","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"2026012006550576000_81.2.121.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.21554"},{"key":"2026012006550576000_81.2.121.25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-199716060-00001","article-title":"Asthma mortality and antipsychotic or sedative use. What is the link?","volume":"16","author":"Joseph","year":"1997","journal-title":"Drug Saf"},{"key":"2026012006550576000_81.2.121.26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01967-2015"},{"key":"2026012006550576000_81.2.121.27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/jsr.12495","article-title":"Gabapentin acutely increases the apnea-hypopnea index in older men: data from a randomized, double-blind, placebo-controlled study","volume":"26","author":"Piovezan","year":"2017","journal-title":"J Sleep Res"},{"key":"2026012006550576000_81.2.121.28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1213\/ANE.0000000000001719","article-title":"Multimodal analgesic therapy with gabapentin and its association with postoperative respiratory depression","volume":"125","author":"Cavalcante","year":"2017","journal-title":"Anesth Analg"},{"key":"2026012006550576000_81.2.121.29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2106\/JBJS.19.00889","article-title":"Dose-dependent association of gabapentinoids with pulmonary complications after total hip and knee arthroplasties","volume":"102","author":"Ohnuma","year":"2020","journal-title":"J Bone Joint Surg Am"},{"key":"2026012006550576000_81.2.121.30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/03007995.2021.1900092","article-title":"Association of gabapentinoid utilization with postoperative pulmonary complications in gynecologic surgery: a retrospective cohort study","volume":"37","author":"Tan","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2026012006550576000_81.2.121.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112807"},{"key":"2026012006550576000_81.2.121.32","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.30"},{"key":"2026012006550576000_81.2.121.33","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.5_suppl_1.251S"},{"key":"2026012006550576000_81.2.121.34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1365-2222.1999.00004.x-i2","article-title":"Differences and similarities between chronic obstructive pulmonary disease and asthma","volume":"29","author":"Jeffery","year":"1999","journal-title":"Clin Experimental Allergy"},{"key":"2026012006550576000_81.2.121.35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s40138-019-00182-5","article-title":"Cardiovascular safety of gabapentinoids","volume":"7","author":"Buckley","year":"2019","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"2026012006550576000_81.2.121.36","doi-asserted-by":"publisher","DOI":"10.2165\/11536200-000000000-00000"},{"key":"2026012006550576000_81.2.121.37","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(23)00187-X","article-title":"Cough and cough hypersensitivity as treatable traits of asthma","volume":"11","author":"Lai","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012006550576000_81.2.121.38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.alit.2022.07.001","article-title":"Identification of asthma cases in Japan using health insurance claims data: Positive and negative predictive values of proposed discrimination criteria: a single-center study","volume":"72","author":"Hamada","year":"2023","journal-title":"Allergol Int"},{"key":"2026012006550576000_81.2.121.39","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00122-2024","article-title":"Epidemiology of patients with severe asthma in Japan: a nationwide descriptive study","volume":"10","author":"Kimura","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026012006550576000_81.2.121.40","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1111\/jgs.17312","article-title":"Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain","volume":"69","author":"Read","year":"2021","journal-title":"J Am Geriatr Soc"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:55:57Z","timestamp":1768920957000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,24]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,15]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/thorax-2025-223240"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223240","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,24]]}}}